Published in J Nutr on August 01, 2008
EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A (2010) 2.48
Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev (2013) 1.44
Nongallated compared with gallated flavan-3-ols in green and black tea are more bioavailable. J Nutr (2008) 1.08
Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem (2009) 0.94
Tea drinking and cognitive function in oldest-old Chinese. J Nutr Health Aging (2012) 0.93
Targeting NADPH oxidase and phospholipases A2 in Alzheimer's disease. Mol Neurobiol (2010) 0.88
Dietary (-)-epicatechin as a potent inhibitor of βγ-secretase amyloid precursor protein processing. Neurobiol Aging (2014) 0.87
Epigallocatechin-3-gallate suppresses 1-methyl-4-phenyl-pyridine-induced oxidative stress in PC12 cells via the SIRT1/PGC-1α signaling pathway. BMC Complement Altern Med (2012) 0.86
Tea and health: preventive and therapeutic usefulness in the elderly? Curr Opin Clin Nutr Metab Care (2009) 0.85
Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease. J Neural Transm (Vienna) (2010) 0.84
Medicinal chemistry of the epigenetic diet and caloric restriction. Curr Med Chem (2013) 0.83
Nutrition and the risk of Alzheimer's disease. Biomed Res Int (2013) 0.82
Banana by-products: an under-utilized renewable food biomass with great potential. J Food Sci Technol (2012) 0.82
Pu-erh tea extract induces the degradation of FET family proteins involved in the pathogenesis of amyotrophic lateral sclerosis. Biomed Res Int (2014) 0.82
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutr J (2016) 0.81
Influence of pH on the speciation of copper(II) in reactions with the green tea polyphenols, epigallocatechin gallate and gallic acid. J Inorg Biochem (2011) 0.79
Pu-erh Tea Protects the Nervous System by Inhibiting the Expression of Metabotropic Glutamate Receptor 5. Mol Neurobiol (2016) 0.76
Herbal Medicine for the Treatment of Vascular Dementia: An Overview of Scientific Evidence. Evid Based Complement Alternat Med (2016) 0.75
Allograft pretreatment for the repair of sciatic nerve defects: green tea polyphenols versus radiation. Neural Regen Res (2015) 0.75
Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease. J Nutr (2017) 0.75
Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci (2004) 5.37
Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem (2004) 1.43
The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci (2004) 1.42
Role of iron in neurodegenerative disorders. Top Magn Reson Imaging (2006) 1.40
Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic Biol Med (2004) 1.34
Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem (2002) 1.30
Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem (2005) 1.27
The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem (2011) 1.26
Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J Neurochem (2004) 1.24
Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci (2005) 1.23
Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals (2005) 1.21
Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol Nutr Food Res (2006) 1.21
Metallocorroles as cytoprotective agents against oxidative and nitrative stress in cellular models of neurodegeneration. J Neurochem (2010) 1.19
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev (2005) 1.17
A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener (2012) 1.13
Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr (2009) 1.12
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol (2010) 1.11
Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem Pharmacol (2002) 1.10
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J (2005) 1.09
Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res (2004) 1.08
Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res (2009) 1.04
Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J Alzheimers Dis (2008) 1.04
Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology (2004) 1.03
Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J (2009) 1.03
Neuroprotective strategies in Parkinson's disease : an update on progress. CNS Drugs (2003) 1.02
Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci Ther (2008) 1.02
Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J Neurochem (2006) 0.99
Striatal dopa and glucose metabolism in PD patients with freezing of gait. Mov Disord (2006) 0.99
Redox imbalance. Cell Tissue Res (2004) 0.98
Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J (2004) 0.98
Manganese corroles prevent intracellular nitration and subsequent death of insulin-producing cells. ACS Chem Biol (2009) 0.98
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett (2004) 0.97
A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. Biol Psychiatry (2009) 0.97
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic Biol Med (2013) 0.95
Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol (2003) 0.95
Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J (2007) 0.95
Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem (2006) 0.95
A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Free Radic Biol Med (2007) 0.95
Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem (2002) 0.94
Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal (2010) 0.93
Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J Alzheimers Dis (2011) 0.93
Binding preference of p62 towards LC3-ll during dopaminergic neurotoxin-induced impairment of autophagic flux. Autophagy (2011) 0.92
cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J (2003) 0.92
Rasagiline in Parkinson's disease. N Engl J Med (2010) 0.92
Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res (2009) 0.92
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J Mol Neurosci (2004) 0.92
Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol (2007) 0.92
An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett (2002) 0.92
Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem Res (2002) 0.91
Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol (2004) 0.91
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem (2007) 0.91
Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res (2007) 0.91
The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases. J Neurochem (2007) 0.90
Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J (2007) 0.90
Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem Biol (2010) 0.90
Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology (Berl) (2002) 0.90
Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem (2003) 0.90
Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. Parkinsonism Relat Disord (2014) 0.89
Green tea polyphenol (-) -epigallocatechin-3-gallate promotes the rapid protein kinase C- and proteasome-mediated degradation of Bad: implications for neuroprotection. J Neurochem (2006) 0.89
Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci (2005) 0.89
Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. Trends Pharmacol Sci (2003) 0.89
The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex. Int J Neuropsychopharmacol (2005) 0.88
Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J Med Chem (2004) 0.88